ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study. (July 2017)

• Record Type: Journal Article
• Authors: Moscetti, Luca; Mentuccia, Lucia; Vici, Patrizia; Quadrini, Silvia; Sperduti, Isabella; Pizzuti, Laura; Fabbri, Maria Agnese; Vaccaro, Angela; Maugeri-Saccà, Marcello; Barba, Maddalena; Sergi, Domenico; Zampa, Germano; Gamucci, Teresa
• Is Part Of: Future oncology. Volume 13:Number 17(2017)
• Page Start: 1517
• Page End: 1525
• Publication Date: 2017-07
• Subjects: Edmonton symptoms assessment scale -- eribulin mesylate -- metastatic breast cancer -- quality of life; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0062
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations.Patients & methods: A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires.Results: A significant ESAS score improvement was observed with a 10% median decrease. No differences were revealed for the QoL scores.Conclusion: The analysis of ESAS and Functional Assessment of Cancer Therapy scores showed that eribulin mesylate contributes to preserve QoL in MBC patients.